Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
Maw, May Tun Hla [1 ]
Malik, Laeeq [1 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, ACT, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
206
引用
收藏
页码：127 / 127
页数：1
相关论文
共 50 条
  • [1] QUALITATIVE EXPLORATION OF THE REAL-WORLD EXPERIENCES OF MEN RECEIVING OR REFUSING CHEMOTHERAPY (DOCETAXEL) FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Ito, T.
    Grant, L.
    Mills, A.
    Heselwood, A.
    Gater, A.
    VALUE IN HEALTH, 2017, 20 (09) : A450 - A450
  • [2] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Apalutamide toxicity and tolerability: A real-world multicentre experience in metastatic hormone-sensitive prostate cancer (MHSPC) in the United Kingdom (UK).
    Ramamurthy, Sindhu
    Elumalai, Thiraviyam
    Pearson, Rachel
    Bolnykh, Iakov
    Muhammad-Afzal, Tehreem
    Olukiran, Gbenro
    Arora, Ananya
    Bradley, Gay
    Taft, Kate
    Myint, Nayan Lin
    Htike, Ei The
    Ince, Will
    Jiang, Xue Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [4] A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Heidegger, Isabel
    Bektic, Jasmin
    Kafka, Mona
    van den Bergh, Roderick C. N.
    Hunting, Jarmo C. B.
    Thomas, Anita
    Brandt, Maximilian P.
    Hoefner, Thomas
    Debedde, Eliott
    Thibault, Constance
    Ermacora, Paola
    Zattoni, Fabio
    Foti, Silvia
    Kretschmer, Alexander
    Ploussard, Guillaume
    Rodler, Severin
    von Amsberg, Gunhild
    Tilki, Derya
    Surcel, Christian
    Rosenzweig, Barak
    Gadot, Moran
    Gandaglia, Giorgio
    Dotzauer, Robert
    CANCER MEDICINE, 2021, 10 (18): : 6354 - 6364
  • [5] Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
    Goebell, P. J.
    Shah, R.
    Raina, R.
    Rege, S.
    Chen, S. L.
    Lee, V. E.
    Waldeck, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S660 - S661
  • [6] Comment on Real-world Efficacy and Toxicity Analysis of Abiraterone Acetate versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer in Asian Patients
    Sudhakaran, Gokul
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [7] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [8] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [9] LACK OF CONCORDANCE BETWEEN REAL-WORLD TREATMENT PATTERNS AND CLINICAL GUIDELINE RECOMMENDATIONS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) PATIENTS
    Goebell, P. J.
    Shah, R.
    Raina, R.
    Rege, S.
    Chen, S.
    Partridge, J.
    Waldeck, R.
    VALUE IN HEALTH, 2022, 25 (07) : S497 - S497
  • [10] Docetaxel for hormone-sensitive metastatic prostate cancer
    Baker, Holly
    LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
12345